Scholar Rock Secures $550M Non-Dilutive Debt Facility, Advances SMA Drug Towards US & EU Launch

summarizeSummary

Scholar Rock announced a new non-dilutive debt facility of up to $550 million and provided positive updates on the regulatory progress for its lead SMA drug, apitegromab, despite reporting widened net losses for Q4 and full-year 2025.

check_boxKey Events

• Secured $550M Non-Dilutive Debt Facility

  Scholar Rock obtained a new debt facility of up to $550 million from Blue Owl Capital, providing non-dilutive capital to fund apitegromab commercialization and pipeline development. This includes $100 million available at closing, an additional $100 million in Q1 2026, up to $150 million upon FDA approval, and an option for $200 million more.

• Positive Apitegromab Regulatory Update

  The FDA completed a constructive meeting with Catalent Indiana, the manufacturing facility for apitegromab, with no additional corrective actions requested. Scholar Rock plans to resubmit its Biologics License Application (BLA) following a successful FDA reinspection of the site, with U.S. launch anticipated in 2026.

• European Market Authorization Progress

  The European Medicines Agency (EMA) review for apitegromab's Marketing Authorisation Application (MAA) is ongoing, with a decision expected in mid-2026 and a European launch planned for the second half of 2026, starting with Germany.

• Widened Net Losses Reported

  The company reported a widened net loss of $91.0 million for Q4 2025, compared to $66.5 million in Q4 2024, and a full-year 2025 net loss of $377.9 million, up from $246.3 million in 2024.

auto_awesomeAnalysis

Scholar Rock has secured a substantial non-dilutive debt facility of up to $550 million, significantly bolstering its financial position to support the commercialization of apitegromab and advance its pipeline. This financing is critical for a pre-revenue biotech, providing a long runway without immediate shareholder dilution. Concurrently, the company provided positive updates on the regulatory path for apitegromab, indicating constructive engagement with the FDA regarding manufacturing site remediation and ongoing EMA review, which de-risks the path to market. While the company reported widened net losses for Q4 and full-year 2025, the strategic financing and regulatory progress are more impactful for the company's long-term prospects.